EraCal Therapeutics

Chemical & Engineering News (C&EN): Keeping you up to date with the chemistry news that matters most. Published by the American Chemical Society.

EraCal Therapeutics is developing a novel oral-active anti-obesity drug, Era-379, identified using the company's state-of-the-art, zebrafish-based platform technology. EraCal is raising a series A to generate human proof-of-concept data for Era-379 and ex

The start-up that developed the compound is a finalist for The Spinoff Prize.

University-bred entrepreneurs are bringing some of the hottest scientific discoveries into practical applications in medicine and technology.

The UZH news ( English Deutsch ) tells our initial StartUp journey towards a new therapeutic solution for obesity.

The UZH news ( English Deutsch ) tells our initial StartUp journey towards a new therapeutic solution for obesity.

Swiss biotech EraCal Therapeutics' founding team, Dr. Josua Jordi and Dr. Simon Breitler, received the BioBusiness-MIT Alumni Life Science Angels award for their business idea, as part of the "BioBusiness" continuing education program at the Università de

EraCal Therapeutics is among the top 10 in the "Health & Nutrition" vertical of the venture business plan competition 2019 . venture is Switzerland's leading startup contest for entrepreneurs with high-tech business ideas.

The University of Zurich and EraCal start a new joint-project by applying the zebrafish technology towards appetite-stimulants. The program is part of the Swiss Innovation Power framework led by Innosuisse.